

Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump® system.

Zurich, SWITZERLAND – 16 April 2015. Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system.

The alfapump system is an automated, fully implantable pump system for the management of ascites. Ascites is a frequent complication of late-stage liver disease and certain cancers, and affects hundreds of thousands of patients across the world.

Under the terms of the agreement, Fresenius Medical Care has the rights to distribute the alfapump system across Europe, Middle East and Africa markets not currently serviced by Sequana Medical's own distribution channels. The first countries to go live are Austria, Belgium, the Netherlands and Poland. Fresenius Medical Care will also engage in collaborative market development and reimbursement programs in these markets.

The alfapump system is the first real alternative to large-volume paracentesis, a lengthy, invasive and painful procedure which can require weekly hospital visits for drainage of excess fluid. By moving ascites to the bladder as it forms, the alfapump system prevents the build-up of fluid and its complications, improving patient quality of life and reducing hospital visits.

Sequana Medical has recently launched its next generation product, alfapump with DirectLink Technology, which allows clinicians to monitor the alfapump remotely. The Company also began an FDA trial of the alfapump system earlier this month.

Gunther Klotz, Executive Vice President Central Europe & Northern Europe, Fresenius Medical Care commented: "The alfapump is a unique innovation that both improves the quality of healthcare and reduces the cost and burden of managing refractory ascites. Together with our Prometheus System, the alfapump therapy will strengthen our portfolio in the management of liver disease. We are delighted to be working with Sequana Medical to bring this therapy to a greater audience."

Dr. Noel L. Johnson, CEO, Sequana Medical added: "We are very excited about this agreement with Fresenius Medical Care, proven market leader and visionary in fluid management. Fresenius Medical has made a commitment to the alfapump therapy and will now leverage their distribution and marketing capabilities to accelerate its adoption and usage throughout the targeted markets. This is the first of several strategic initiatives we are working on to partner with world-class medical device companies to apply our technology to improve the management of patients suffering from fluid

overload. Ascites management is an area of significant unmet clinical need and represents more than a €1 billion market opportunity within the EMEA markets.”

Notes to Editors:

About Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.6 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is also a world's leading provider of extracorporeal systems such as the Prometheus System for patients with liver failure. For more information about Fresenius Medical Care, visit the company's website at www.freseniusmedicalcare.com.

About Sequana Medical

Founded in 2006, Sequana Medical AG is a Swiss medical device company backed by NeoMed Management, VI Partners, Biomed Invest, Capricorn Venture Partners, Entrepreneurs Fund and Life Science Partners, and is dedicated to improving patient lives through innovative technologies to manage fluid overload in patients suffering from liver disease, cancer and congestive heart failure. For more information please visit www.sequanamedical.com.

About alfapump with DirectLink technology

The alfapump system, which is implanted beneath the skin of the abdomen, is similar in size to an internal defibrillator and works by pumping fluid from the abdomen into the bladder, where it is removed from the body naturally through urination. The system has CE-Mark approval for the removal of refractory ascites in liver and cancer patients.

DirectLink Technology allows remote monitoring of pump activity, providing physicians with a periodic overview of alfapump system activity. Should an alfapump system parameter, such as battery level, fall outside of a defined range, the physician can be alerted to take appropriate action.

The new generation alfapump system with DirectLink Technology allows ascites patients to live free from the need for repeat large volume paracentesis, achieving better quality of life by reducing the number of visits to the hospital and avoiding the risk of current therapeutic options.

For more information please visit www.alfapump.com.

About Refractory Ascites

In patients with refractory ascites, up to 15 litres of fluid can gather around the abdominal organs and it is impossible for this fluid to be removed from the body through medication. Ascites can make patients look pregnant, as well as being painful and taking away the appetite, making patients weak and leading to malnutrition. These patients may have to make weekly or monthly trips to the hospital in order to have the fluid drained from their abdomen by paracentesis. The alfapump provides a simple solution to ascites fluid management and experts hope it could even help the liver regenerate.

Contact

Sequana Medical

Emily Woodward

Director of Marketing

emily.woodward@sequanamedical.com

Phone +41 44 403 55 21

www.sequanamedical.com

www.alfapump.com